FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ı	96	hin	nto	n	D	C	2054	q			

OMB APPROVAL

hours per response

н		
ı		3235-0287
ı	Estimated average burden	

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* PFIZER INC						2. Issuer Name and Ticker or Trading Symbol Mirna Therapeutics, Inc. [MIRN]								ationship of k all applical Director		y Perso X	,	
(Last) (First) (Middle) 235 EAST 42ND STREET						3. Date of Earliest Transaction (Month/Day/Year) 10/05/2015								Officer (g below)	give title		Other (s below)	pecify
(Street) NEW YORK NY 10017					4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person													
(City)	(S	tate)	(Zip)															
			able I - No			_			Dis									
1. Title of Security (Instr. 3)					2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			5. Amount Securities Beneficiall Owned Fol	у	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
									v	Amount	(A) or (D)		rice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common	Stock			10/05	5/2015		С		1,539,	224	A	\$0 ⁽¹⁾	1,539	,224		D		
Common	Stock			10/06	/2015			P		714,2	85	A	\$7	2,253	,509	D		
Common Stock 10/06					6/2015		J ⁽²⁾		235,855 A		\$7	2,489,364		D				
							ities Acqı warrants	,			,		•	wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date if any (Month/Day/Yea	Code (Inst				6. Date Exercis Expiration Date (Month/Day/Ye		е	7. Title and Amour Securities Underly Derivative Securit (Instr. 3 and 4)		rlying	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reporter Transac	ive ties cially ing ed	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	de V	(A)	(D)	Date Exercisal		Expiration Date	Title		unt or ber of es		(Instr. 4)			
Series C Convertible Preferred Stock	(1)	10/05/2015		C			1,047,806	(1)		(1)	Common Stock	1,04	17,806	(1)	0.00	00	D	
Series D Convertible Preferred	(1)	10/05/2015		C			491,418	(1)		(1)	Common Stock	49	1,418	(1)	0.00	00	D	

Explanation of Responses:

Stock

- 1. Each share of the issuer's Series C Convertible and Series D Convertible Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and has no expiration date.
- 2. The reporting person received 235,855 shares of Common Stock as a payment-in-kind dividend in connection with the conversion of the reporting person's Series C Convertible and Series D Convertible Preferred Stock into shares of Common Stock.

/s/ Susan Grant, Assistant Secretary on behalf of Pfizer Inc.

10/07/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.